Viking’s VK2809 demonstrates positive effect in POC study in glycogen storage disease
GSD Ia is a rare, orphan genetic disease that results in excess accumulation of glycogen and lipids in liver tissue. Data to date showed that treatment with VK2809
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The US Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is available in a prefilled pen